AbbVie lifts full-year outlook as Skyrizi and Rinvoq drive $15B in Q1 revenue
AbbVie (NYSE:ABBV) reported financial results for the first quarter ended March 31, 2026, demonstrating the successful evolution of its portfolio following the loss of exclusivity for Humira.


_1389491_640x360_2498175043705-640x360.webp&w=3840&q=75)
_1389474_640x360_2498176067588-640x360.webp&w=3840&q=75)
_1389438_640x360_2498174531900-640x360.webp&w=3840&q=75)
_1389440_640x360_2498174531826-640x360.webp&w=3840&q=75)




_1389365_640x360_2498170947835-640x360.webp&w=3840&q=75)
